Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma.

MLA

Wang, Chunmiao, et al. “Targeted Blocking of EGFR and GLUT1 by Compound H Reveals a New Strategy for Treatment of Triple-Negative Breast Cancer and Nasopharyngeal Carcinoma.” European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, vol. 198, July 2024, p. 106789. EBSCOhost, https://doi.org/10.1016/j.ejps.2024.106789.

APA

Wang, C., Li, Z., Zhai, H., Shen, X., Li, F., Zhang, Q., Li, D., & Hou, H. (2024). Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 198, 106789. https://doi.org/10.1016/j.ejps.2024.106789

Chicago

Wang, Chunmiao, Zhaoquan Li, Honglan Zhai, Xiaoyan Shen, Fengming Li, Qiuping Zhang, Danrong Li, and Huaxin Hou. 2024. “Targeted Blocking of EGFR and GLUT1 by Compound H Reveals a New Strategy for Treatment of Triple-Negative Breast Cancer and Nasopharyngeal Carcinoma.” European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences 198 (July): 106789. doi:10.1016/j.ejps.2024.106789.